Periprocedural myocardial infarction (PMI), a common complication after percutaneous coronary intervention (PCI), is associated with an increased risk of mortality. Inflammation is pivotal in the initiation, progression and prognosis of arteriosclerotic cardiovascular disease (ASCVD). Studies showed that inflammation plays an important role in the PMI. Statin therapy can both lipid-lowering and anti-inflammatory effects. Pretreatment with high-dose statin may have a lower incidence of PMI and improve clinical outcomes in patients with coronary heart disease undergoing PCI. The main purpose of this review is to analyze the relationships between inflammation, statin loading and PMI.